Silence Therapeutics shares fall on heavy volume

Shares of Silence Therapeutics slid sharply on Tuesday, extending losses after the company provided no new clinical or corporate updates to justify its recent valuation.

The London-listed biotech’s stock fell 15% by midday, trading at 285 pence per share, with turnover more than double its 30-day average. The decline followed a period of relative stability in which the company’s shares had fluctuated within a narrow range, suggesting investor patience was wearing thin.

Silence Therapeutics has not disclosed any material developments regarding its pipeline of RNA-based therapies or corporate strategy since its last update in March. Analysts noted the absence of catalysts typically drives volatility in small-cap biotech stocks, where sentiment is highly sensitive to news flow.

The company’s lead programs remain in early-stage clinical trials, with no regulatory milestones or partnership announcements expected in the near term. This lack of visibility contrasts with broader biotech indices, which have shown resilience amid improving macroeconomic conditions.

Investors attributed the selloff to a combination of profit-taking and reduced risk appetite for unprofitable biotechs, particularly those without near-term revenue prospects. Silence Therapeutics has yet to generate commercial revenue, relying instead on periodic equity raises to fund operations.

The stock’s decline underscores the challenges facing early-stage biotech firms in maintaining investor interest during periods of market uncertainty. Silence Therapeutics did not respond to requests for comment.